Exhibit 1
Irrevocable
Proxy and Power of Attorney
Pursuant
to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation
(the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”),
dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placement Agent Agreement (the
“Amendment”), dated December 10, 2024 (the “Consulting Agreement”), the Corporation is obligated to issue
to Spartan up to 1,050,000 shares (“Consultant Shares”) of Series C Convertible Preferred Stock, par value $0.0001
per share, of the Corporation (the “Series C Preferred Stock”), convertible into up to 1,050,000 shares (“Conversion
Shares”) of common stock, par value $0.0001 per share, of the Corporation (the “Common Stock”) in consideration
for advisory and consultant services that have been and will be rendered by Spartan and (ii) placement agent agreement, dated
December 5, 2024, as amended the Amendment, by and between the Corporation and Spartan (the “Placement Agent Agreement”),
the Corporation has agreed to issue Spartan common stock purchase warrants exercisable for a number of shares of Common Stock
(collectively, the “Warrant Shares”) equal to 10% of the number of shares of Series B non-voting convertible preferred
stock of the Corporation, par value $0.0001 per share, sold in a private placement by the Corporation (the “Offering”)
for which Spartan is serving as placement agent. Spartan is executing this Irrevocable Proxy and Power of Attorney (this “Irrevocable
Proxy”) as a material inducement for the Corporation’s entering into the Consulting Agreement and the Placement Agent
Agreement.
Upon
the issuance of any and all Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable), Spartan (x) will be the
record holder of the Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable) and (y) will have good and valid
title to such Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable), free and clear of any liens or restrictions
on transfer except as provided herein and in the Consulting Agreement and Placement Agent Agreement. Upon the issuance by the
Corporation of a number of Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable) to Spartan and/or its Affiliates
(as defined under Rule 405 of the Securities Act of 1933, as amended) or any other person or entity acting as a group together
with Spartan and such Affiliates (such persons, “Attribution Parties”), Spartan (and such other Attribution Parties,
if any) hereby irrevocably appoints Dr. Jonathan Kaufman, Chief Executive Officer of the Corporation (the “Principal Stockholder”),
and any designee of the Principal Stockholder as the proxy and attorney-in-fact, with full power of substitution and resubstitution,
to represent and vote the aggregate number of Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable), held
by Spartan (and such Attribution Party, if any) (such shares collectively, the “Proxied Shares”), whether at a meeting
of the shareholders of the Corporation or by any consent to any action taken by such shareholders without a meeting, with respect
to any and all matters presented to the shareholders of the Corporation for vote or for action without a meeting. Such irrevocable
appointment to the Principal Stockholder of the aforementioned rights to the Proxied Shares shall be evidenced by the signature
of each of Spartan, such Attribution Party (if any) and the Principal Stockholder on the row of Schedule I attached hereto
corresponding to such Proxied Shares. This proxy and power of attorney granted by Spartan (and any other Attribution Party, if
any) shall be irrevocable during its term and shall be deemed to be coupled with an interest sufficient in law to support an irrevocable
proxy. Spartan authorizes the Principal Stockholder to file this Irrevocable Proxy and any substitution or revocation with the
Corporation so that the existence of this Irrevocable Proxy is noted on the books and records of the Corporation. The power of
attorney granted by Spartan herein is a durable power of attorney and shall survive the dissolution, bankruptcy, death or incapacity
of Spartan.
During
the effectiveness of this Irrevocable Proxy, the Principal Stockholder shall have all the voting power and all power to grant
consent that Spartan (or an Attribution Party, if any) would possess by virtue of being the holder of the Consultant Shares, Conversion
Shares and/or Warrant Shares (as applicable). Upon each signature by Spartan (and any other Attribution Party) on Schedule
I with respect to Proxied Shares, Spartan and such Attribution Party hereby ratifies and confirms all acts that the Principal
Stockholder will do or cause to be done with respect to such Proxied Shares by virtue of and within the limitations set forth
in this Irrevocable Proxy.
This
Irrevocable Proxy is binding on Spartan’s heirs, estate, executors, personal representatives, successors, and assigns (including
any transferee of any of the Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable)) to the fullest extent
permitted under applicable law.
Spartan
shall not dispose of, pledge, sell, convey, assign, hypothecate, or otherwise transfer (each, a “Transfer”) number
of Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable) without the express prior consent of the Corporation
and shall provide the Corporation with at least five (5) Business Days’ prior notice of its intention to effect a Transfer
to a non-Attribution Party. “Business Day” shall mean any day except any Saturday, any Sunday, any day which is a
federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is closed and/or The Nasdaq
Stock Market LLC is not open for at least five (5) hours of trading. Spartan shall inform the Corporation of any pledge of Proxied
Shares made prior to the date of this Irrevocable Proxy. Except pursuant to this Irrevocable Proxy, as of the date hereof, no
person or entity other than Spartan or an Attribution Party has any contractual or other right or obligation to purchase or otherwise
acquire any of the Consultant Shares, Conversion Shares and/or Warrant Shares (as applicable). Upon the registration of the reoffer
and resale of the Conversion Shares and Warrant Shares (as applicable) listed on Schedule I, the appointment of voting
power granted to the Principal Stockholder shall immediately terminate with respect to such respective Conversion Shares and the
corresponding Consultant Shares, and Warrant Shares (as applicable) and all restrictions on, and consents required for, Transfers
of the Consultant Shares, Conversion Shares and Warrant Shares shall terminate, provided, that Spartan hereby agrees that
neither Spartan, the other Attribution Parties nor their respective designees, successors or assigns, shall Transfer any Consultant
Shares, Conversion Shares or Warrant Shares to a non-Attribution Party (other than to the Corporation or the Principal Stockholder)
(i) whose business is directly or indirectly competitive with the business of the Corporation as it is being conducted or planned
to be conducted at the time of such proposed disposition, or (ii) who intends to or has taken action, directly or indirectly,
in one or more related transactions, towards obtaining an ownership interest in the Corporation for purposes of effecting (x)
a change of “control” of the Corporation (as such term is defined under Section 203 of the General Corporation Law
of the State of Delaware), (y) a sale or all or substantially all of the assets of the Corporation or (z) a change to the board
of directors or management of the Corporation at the time of such proposed disposition, (iii) if such disposition will, to Spartan’s
knowledge, result in such third party (together with all of such third party’s “affiliates” (as defined in Rule
405 of the Securities Act of 1933, as amended) and any other persons acting as a group together with such third party) being deemed
a “beneficial owner” (as defined under Rule 13d-3) of more than 4.99% of the outstanding shares of Common Stock immediately
after giving effect to such disposition. In addition, this Irrevocable Proxy shall terminate with respect to Consultant Shares,
Conversion Shares and Warrant Shares (as applicable) upon each disposition of Consultant Shares, Conversion Shares and Warrant
Shares (as applicable) by an Attribution Party to a non-Attribution Party. Notwithstanding the foregoing, a Transfer of Consultant
Shares, Conversion Shares or Warrant Shares by Spartan (or any other Attribution Party) to an Attribution Party shall only become
effective upon such transferee’s delivery of a completed and executed Joinder Agreement, substantially in the form attached
hereto as Schedule II. The Company undertakes to include the maximum possible number of Conversion Shares and Warrant Shares
in the initial registration statement filed in connection with the Offering and in each subsequent registration statement, as
needed, and agrees to lift all Transfer and notice restrictions six months after any issuance if such Conversion Shares and Warrant
Shares are not then registered for resale.
This
Irrevocable Proxy may be amended or supplemented, and any obligation of an Attribution Party may be waived, only with the prior
written consent of the Corporation. No waivers of any breach of this Irrevocable Proxy extended by the Corporation to any Attribution
Party shall be construed as a waiver of any rights or remedies of the Corporation or with respect to any subsequent breach.
This
Irrevocable Proxy shall be governed by, and construed under, the laws of the State of Delaware, without regard to principles of
conflict of laws. In case any provision of this Irrevocable Proxy shall be invalid, illegal or unenforceable, it shall to the
extent practicable, be modified so as to make it valid, legal and enforceable and to retain as nearly as practicable the intent
of the Corporation and Spartan (and any other Attribution Party, if any) represented by such invalidated term, and the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
In
the event that any signature hereto is delivered by facsimile transmission or by an e-mail which contains a portable document
format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original
thereof.
[signature
page follows]
Spartan,
hereby revoking any and all prior proxies granted by Spartan with respect to the Consultant Shares, Conversion Shares and Warrant
Shares (as applicable), has executed this Irrevocable Proxy on the date set forth below to be deemed effective as of December
20, 2024.
|
|
SPARTAN CAPITAL SECURITIES,
LLC |
|
|
|
|
By: |
/s/ Kim
Monchik |
|
|
Name: Kim Monchik |
|
|
Title: Chief Administrative Officer |
|
|
|
|
Date: |
12/20/2024 |
|
|
|
ACKNOWLEDGED AND AGREED TO BY: |
|
|
|
/s/
Jonathan Kaufman |
|
Name: Jonathan Kaufman |
|
|
|
|
Date: |
December
20, 2024 |
|
|
|
|
Schedule
I
Date |
Number
of Conversion
Shares as of such date |
Number
of Warrant
Shares as of such
date |
Signature
of Authorized
Signatory of Spartan (and/or
Attribution Party, if any) |
Acknowledgement
and Acceptance of
Principal Stockholder |
12/23/2024 |
182,076 |
85,421 |
Signature:
/s/ Kim Monchik |
Signature:
/s/ Jonathan Kaufman |
12/23/2024 |
78,032 |
0 |
Signature:
/s/ Eric Meyer |
12/31/2024 |
30,053 |
11,795 |
Signature:
/s/ Kim Monchik |
Signature:
/s/ Jonathan Kaufman |
12/31/2024 |
12,880 |
0 |
Signature:
/s/ Eric Meyer |
2/27/2025 |
309,353 |
88,083 |
Signature:
/s/ Kim Monchik |
Signature:
/s/ Jonathan Kaufman |
2/27/2025 |
132,580 |
37,750 |
Signature:
/s/ Eric Meyer |
3/10/2025 |
59,290 |
20,247 |
Signature:
/s/ Kim Monchik |
Signature:
/s/ Jonathan Kaufman |
3/10/2025 |
25,410 |
8,677 |
Signature:
/s/ Eric Meyer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule
II
Joinder
Agreement
In
connection with the Transfer from [Spartan/other Attribution Party] to the undersigned of
[Consultant Shares/Conversion Shares/Warrant Shares], the undersigned is executing and delivering this Joinder Agreement to the
Irrevocable Proxy and Power of Attorney, dated as of December 20, 2024 (the “Irrevocable Proxy”). Terms used but not
defined herein shall have the same meanings ascribed to them as in the Irrevocable Proxy.
By
executing and delivering this Joinder Agreement to the Corporation and [Spartan/ other Attribution
Party], the undersigned hereby agrees to become a party to, to be bound by, and to comply with the provisions of the Irrevocable
Proxy in the same manner as if the undersigned were an original signatory to the Irrevocable Proxy. This Joinder Agreement shall
become an integral part of, and undersigned shall become a party to and be bound by the Irrevocable Proxy upon execution and delivery
of this Joinder Agreement by the undersigned.
Accordingly,
the undersigned has executed and delivered this Joinder Agreement as of ,
.
________________________
Address
for notices:
Email:
Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From Feb 2025 to Mar 2025
Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From Mar 2024 to Mar 2025